Maravai LifeSciences Holdings, Inc.

Symbol: MRVI

NASDAQ

9.86

USD

Market price today

  • -9.9573

    P/E Ratio

  • -0.0063

    PEG Ratio

  • 2.48B

    MRK Cap

  • 0.00%

    DIV Yield

Maravai LifeSciences Holdings, Inc. (MRVI) Financial Statements

On the chart you can see the default numbers in dynamics for Maravai LifeSciences Holdings, Inc. (MRVI). Companys revenue shows the average of 420.376 M which is 0.398 % gowth. The average gross profit for the whole period is 309.022 M which is 0.565 %. The average gross profit ratio is 0.645 %. The net income growth for the company last year performance is -1.243 % which equals 3.399 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Maravai LifeSciences Holdings, Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to . A look back at the past year reveals a total asset change of -0.348. In the realm of current assets, MRVI clocks in at 699.912 in the reporting currency. A significant portion of these assets, precisely 574.962, is held in cash and short-term investments. This segment shows a change of -0.090% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 8.559, if any, in the reporting currency. This indicates a difference of -24.670% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 518.707 in the reporting currency. This figure signifies a year_over_year change of 0.044%. Shareholder value, as depicted by the total shareholder equity, is valued at 416.753 in the reporting currency. The year over year change in this aspect is -0.236%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 55.723, with an inventory valuation of 51.4, and goodwill valued at 326.03, if any. The total intangible assets, if present, are valued at 220.99. Account payables and short-term debt are 10.73 and 12.85, respectively. The total debt is 610.97, with a net debt of 36.01. Other current liabilities amount to 60.53, adding to the total liabilities of 697.57. Lastly, the referred stock is valued at 0, if it exists.

common:word.in-mln

USD
Growth
TTM202320222021202020192018

balance-sheet.row.cash-and-short-term-investments

2296.43575632.1551.3
236.2
24.7
21.9

balance-sheet.row.short-term-investments

0000
0
0
0

balance-sheet.row.net-receivables

200.7455.7146.8117.5
51
18
16

balance-sheet.row.inventory

197.7951.443.251.6
33.3
14.2
14.3

balance-sheet.row.other-current-assets

73.0117.825.819.7
11.1
3.6
1.6

balance-sheet.row.total-current-assets

2767.97699.9847.9740
331.6
60.6
53.8

balance-sheet.row.property-plant-equipment-net

807.33222.6116.646.3
101.3
94.3
42.6

balance-sheet.row.goodwill

1304.55326283.7152.8
224.3
224.3
224.3

balance-sheet.row.intangible-assets

897.69221216.7117.6
177.7
197.9
218.1

balance-sheet.row.goodwill-and-intangible-assets

2202.23547500.3270.3
401.9
422.1
442.4

balance-sheet.row.long-term-investments

35.818.611.40.5
0
0
0

balance-sheet.row.tax-assets

1764.230765.8808.1
431.7
0
0

balance-sheet.row.other-non-current-assets

-113.59.340.352.9
4.2
0.8
0.9

balance-sheet.row.total-non-current-assets

4696.11787.51434.41178.2
939.1
517.2
485.9

balance-sheet.row.other-assets

0000
0
0
0

balance-sheet.row.total-assets

7464.081487.52282.31918.3
1270.7
577.8
539.7

balance-sheet.row.account-payables

35.0410.768.2
8.2
7.5
3.6

balance-sheet.row.short-term-debt

45.0112.911.79.7
6
2.5
2.5

balance-sheet.row.tax-payables

1111.4
2.9
3
2.1

balance-sheet.row.long-term-debt-total

2192.18518.7573.6524.6
584.8
387.7
337.4

Deferred Revenue Non Current

829.3779.400
389.5
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

21.59---
-
-
-

balance-sheet.row.other-current-liab

209.0360.589.465.7
38.5
18.7
28.7

balance-sheet.row.total-non-current-liabilities

3807.23610.11266.91279.1
985.2
403.6
355.7

balance-sheet.row.other-liabilities

0000
0
0
0

balance-sheet.row.capital-lease-obligations

285.3279.457.83.7
56.2
52.9
1.8

balance-sheet.row.total-liab

4106.89697.61377.11372.9
1115.9
433.2
391.7

balance-sheet.row.preferred-stock

0000
0
0
0

balance-sheet.row.common-stock

10.052.52.62.6
2.6
183.9
182.8

balance-sheet.row.retained-earnings

1349.25285.7404.8184.6
0.9
-42.4
-38.2

balance-sheet.row.accumulated-other-comprehensive-income-loss

0000
0
-0.1
-0.2

balance-sheet.row.other-total-stockholders-equity

507.98128.5137.9128.4
85.1
0
0

balance-sheet.row.total-stockholders-equity

1867.28416.8545.2315.5
88.5
141.4
144.4

balance-sheet.row.total-liabilities-and-stockholders-equity

7464.081487.52282.31918.3
1270.7
577.8
539.7

balance-sheet.row.minority-interest

1489.91373.1360229.9
66.2
3.2
3.6

balance-sheet.row.total-equity

3357.19789.9905.2545.4
154.7
144.6
148

balance-sheet.row.total-liabilities-and-total-equity

7464.08---
-
-
-

Total Investments

35.818.611.40.5
0
0
0

balance-sheet.row.total-debt

2398.63611585.3534.3
590.8
390.2
339.9

balance-sheet.row.net-debt

102.236-46.9-17
354.6
365.5
318

Cash Flow Statement

The financial landscape of Maravai LifeSciences Holdings, Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of -0.883. The company recently extended its share capital by issuing -0.02, marking a difference of -1.605 compared to the previous year. The company's investing activities resulted in net cash usage, amounting to -122310000.000 in the reporting currency. This is a shift of -0.543 from the previous year. In the same period, the company recorded 48.78, 12.87, and -5.77, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated 0 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as -55.3, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM202320222021202020192018

cash-flows.row.net-income

-147.04-119490.7469.3
78.8
-5.2
-16.9

cash-flows.row.depreciation-and-amortization

49.5348.838.124.8
25.8
24.1
22.3

cash-flows.row.deferred-income-tax

756.46754.942.346.9
-5.5
-1.2
0.3

cash-flows.row.stock-based-compensation

40.6634.618.710.5
24.6
1.7
2.1

cash-flows.row.change-in-working-capital

29.597.8-45.1-176.6
35.9
2.3
-15.8

cash-flows.row.account-receivables

19.8784.4-22.3-70.4
-33.1
-1.9
-4.1

cash-flows.row.inventory

4.850.69.5-21.6
-19.1
0.1
2.3

cash-flows.row.account-payables

1.845.3-1.60.7
1.2
2.5
-0.9

cash-flows.row.other-working-capital

17.967.5-30.7-85.3
87
1.6
-13.1

cash-flows.row.other-non-cash-items

-686.93-690.9-8.7-6.2
-7.5
2.4
7.8

cash-flows.row.net-cash-provided-by-operating-activities

32.68000
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-63.35-65.6-17.1-14.8
-25.4
-17.1
-3.6

cash-flows.row.acquisitions-net

75.02-69.6-238.3120
-3
0
0.2

cash-flows.row.purchases-of-investments

0000
0
0
0

cash-flows.row.sales-maturities-of-investments

0000
0
0
0

cash-flows.row.other-investing-activites

6.4212.9-12.20.5
34.5
0
0

cash-flows.row.net-cash-used-for-investing-activites

-56.82-122.3-267.6105.7
6.1
-17.1
-3.5

cash-flows.row.debt-repayment

-5.92-5.8-13.9-6
-412.1
-2.6
-255.2

cash-flows.row.common-stock-issued

-1.4502.41.7
1758.9
0
0

cash-flows.row.common-stock-repurchased

-0.35000
-1458
-0.2
0

cash-flows.row.dividends-paid

0000
-609.3
0
-52.1

cash-flows.row.other-financing-activites

-35.07-55.3-176-154.8
773.7
-1.3
298.1

cash-flows.row.net-cash-used-provided-by-financing-activities

-42.44-61.1-187.5-159
53.2
-4.2
-9.2

cash-flows.row.effect-of-forex-changes-on-cash

01.60-0.1
0
0
-0.1

cash-flows.row.net-change-in-cash

-66.58-57.280.9315.1
211.5
2.8
-12.9

cash-flows.row.cash-at-end-of-period

2296.43575632.1551.3
236.2
24.7
21.9

cash-flows.row.cash-at-beginning-of-period

2363.02632.1551.3236.2
24.7
21.9
34.7

cash-flows.row.operating-cash-flow

32.68126.2536368.6
152.2
24.1
-0.2

cash-flows.row.capital-expenditure

-63.35-65.6-17.1-14.8
-25.4
-17.1
-3.6

cash-flows.row.free-cash-flow

-30.6760.7518.9353.7
126.8
7
-3.8

Income Statement Row

Maravai LifeSciences Holdings, Inc.'s revenue saw a change of -0.673% compared with the previous period. The gross profit of MRVI is reported to be 137.6. The company's operating expenses are 141.8, showing a change of -3.948% from the last year. The expenses for depreciation and amortization are 48.78, which is a -9.382% change from the last accounting period. Operating expenses are reported to be 141.8, which shows a -3.948% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a -1.007% year-over-year growth. The operating income is -4.2, which shows a -1.007% change when compared to the previous year. The change in the net income is -1.243%. The net income for the last year was -119.03.

common:word.in-mln

USD
Growth
TTM202320222021202020192018

income-statement-row.row.total-revenue

274.1288.9883799.2
284.1
143.1
123.8

income-statement-row.row.cost-of-revenue

154151.3169140.6
79.6
66.8
60.8

income-statement-row.row.gross-profit

120.1137.6714658.7
204.4
76.3
63.1

income-statement-row.row.gross-profit-ratio

0000
0
0
0

income-statement-row.row.research-development

18.17---
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-

income-statement-row.row.other-expenses

-1.5-1.3-0.40.3
-7.5
0.1
0.1

income-statement-row.row.operating-expenses

166.92141.8147.6115.3
103.5
52
45.7

income-statement-row.row.cost-and-expenses

320.92293.1316.6255.8
183.2
118.8
106.5

income-statement-row.row.interest-income

28.8927.72.330.3
30.7
30
0

income-statement-row.row.interest-expense

23.245.920.430.3
30.7
30
27.4

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-

income-statement-row.row.total-other-income-expensenet

649.9621.9-22.7-23.9
14.1
-29.8
-6.5

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-

income-statement-row.row.other-operating-expenses

-1.5-1.3-0.40.3
-7.5
0.1
0.1

income-statement-row.row.total-operating-expenses

649.9621.9-22.7-23.9
14.1
-29.8
-6.5

income-statement-row.row.interest-expense

23.245.920.430.3
30.7
30
27.4

income-statement-row.row.depreciation-and-amortization

25.7248.8-5.8-11
25.8
24.5
22.3

income-statement-row.row.ebitda-caps

-19.96---
-
-
-

income-statement-row.row.operating-income

-45.68-4.2574.2554.6
67.6
24
16.4

income-statement-row.row.income-before-tax

599.85617.7551.5530.8
81.7
-5.9
-16.5

income-statement-row.row.income-tax-expense

759.56756.160.861.5
2.9
-0.7
0.4

income-statement-row.row.net-income

-131.04-119490.7469.3
76.9
-5.2
-17.7

Frequently Asked Question

What is Maravai LifeSciences Holdings, Inc. (MRVI) total assets?

Maravai LifeSciences Holdings, Inc. (MRVI) total assets is 1487450000.000.

What is enterprise annual revenue?

The annual revenue is 138320000.000.

What is firm profit margin?

Firm profit margin is 0.438.

What is company free cash flow?

The free cash flow is -0.232.

What is enterprise net profit margin?

The net profit margin is -0.478.

What is firm total revenue?

The total revenue is -0.167.

What is Maravai LifeSciences Holdings, Inc. (MRVI) net profit (net income)?

The net profit (net income) is -119029000.000.

What is firm total debt?

The total debt is 610967000.000.

What is operating expences number?

The operating expences are 141799000.000.

What is company cash figure?

Enretprise cash is 561691000.000.